Metropolitan Life Insurance Company (MetLife)’s Exelixis EXEL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | – | Sell |
-68,816
| Closed | -$1.26M | – | 2388 |
|
|
2021
Q4 | $1.26M | Sell |
68,816
-1,091
| -2% | -$20.9K | 0.02% | 814 |
|
|
2021
Q3 | $1.48M | Sell |
69,907
-2,098
| -3% | -$39K | 0.02% | 692 |
|
|
2021
Q2 | $1.31M | Buy |
72,005
+7,248
| +11% | +$169K | 0.02% | 800 |
|
|
2021
Q1 | $1.46M | Buy |
64,757
+2,878
| +5% | +$65K | 0.02% | 711 |
|
|
2020
Q4 | $1.24M | Sell |
61,879
-1,232
| -2% | -$25.8K | 0.02% | 747 |
|
|
2020
Q3 | $1.54M | Sell |
63,111
-2,800
| -4% | -$65.4K | 0.03% | 519 |
|
|
2020
Q2 | $1.56M | Sell |
65,911
-20,475
| -24% | -$475K | 0.03% | 503 |
|
|
2020
Q1 | $1.49M | Sell |
86,386
-4,661
| -5% | -$85.3K | 0.03% | 500 |
|
|
2019
Q4 | $1.6M | Buy |
91,047
+582
| +0.6% | +$9.87K | 0.03% | 657 |
|
|
2019
Q3 | $1.6M | Sell |
90,465
-10,117
| -10% | -$205K | 0.03% | 609 |
|
|
2019
Q2 | $2.15M | Sell |
100,582
-50
| -0% | -$1.05K | 0.04% | 495 |
|
|
2019
Q1 | $2.4M | Sell |
100,632
-187
| -0.2% | -$4.26K | 0.04% | 396 |
|
|
2018
Q4 | $1.98M | Buy |
100,819
+384
| +0.4% | +$6.85K | 0.04% | 426 |
|
|
2018
Q3 | $1.78M | Buy |
100,435
+77,332
| +335% | +$1.51M | 0.03% | 590 |
|
|
2018
Q2 | $497K | Buy |
23,103
+1,262
| +6% | +$26.1K | 0.01% | 1315 |
|
|
2018
Q1 | $484K | Buy |
21,841
+252
| +1% | +$6.97K | 0.01% | 1299 |
|
|
2017
Q4 | $656K | Sell |
21,589
-203
| -0.9% | -$5.4K | 0.01% | 1095 |
|
|
2017
Q3 | $528K | Buy |
21,792
+1,112
| +5% | +$29.6K | ﹤0.01% | 1658 |
|
|
2017
Q2 | $509K | Sell |
20,680
-134,202
| -87% | -$2.84M | ﹤0.01% | 1674 |
|
|
2017
Q1 | $3.36M | Sell |
154,882
-6,542
| -4% | -$133K | 0.02% | 780 |
|
|
2016
Q4 | $2.41M | Sell |
161,424
-300
| -0.2% | -$4.33K | 0.02% | 906 |
|
|
2016
Q3 | $2.07M | Sell |
161,724
-2,554
| -2% | -$27.6K | 0.02% | 944 |
|
|
2016
Q2 | $1.28M | Buy |
164,278
+6,115
| +4% | +$35.2K | 0.01% | 1121 |
|
|
2016
Q1 | $633K | Buy |
158,163
+820
| +0.5% | +$3.47K | ﹤0.01% | 1443 |
|
|
2015
Q4 | $887K | Hold |
157,343
| – | – | 0.01% | 1251 |
|
|
2015
Q3 | $883K | Buy |
157,343
+50,304
| +47% | +$274K | 0.01% | 1261 |
|
|
2015
Q2 | $402K | Sell |
107,039
-46,576
| -30% | -$151K | ﹤0.01% | 1899 |
|
|
2015
Q1 | $395K | Sell |
153,615
-148
| -0.1% | -$343 | ﹤0.01% | 1684 |
|
|
2014
Q4 | $221K | Hold |
153,763
| – | – | ﹤0.01% | 2347 |
|
|
2014
Q3 | $235K | Buy |
153,763
+44,106
| +40% | +$142K | ﹤0.01% | 2261 |
|
|
2014
Q2 | $372K | Sell |
109,657
-37,733
| -26% | -$130K | ﹤0.01% | 2053 |
|
|
2014
Q1 | $522K | Sell |
147,390
-2,879
| -2% | -$19.6K | ﹤0.01% | 1777 |
|
|
2013
Q4 | $921K | Hold |
150,269
| – | – | 0.01% | 1381 |
|
|
2013
Q3 | $875K | Buy |
150,269
+15,542
| +12% | +$80.4K | 0.01% | 1359 |
|
|
2013
Q2 | $612K | Buy |
+134,727
| New | +$639K | ﹤0.01% | 1564 |
|
Other funds holding EXEL
FCM
MG
Metropolitan Life Insurance Company (MetLife)'s EXEL Position: Q1 2022 in Review
Metropolitan Life Insurance Company (MetLife) sold out of Exelixis (EXEL) in Q1 2022, closing a stake of 68,816 shares — an estimated $1.26M sold.
Metropolitan Life Insurance Company (MetLife) first reported a position in EXEL in Q2 2013 and held it in 35 quarters. The position peaked at $3.36M in Q1 2017. 364 funds tracked by Wall St. Rank hold EXEL as of Q1 2022.
- Metropolitan Life Insurance Company (MetLife) reported no remaining Exelixis position as of Q1 2022 after selling out during the quarter.
- Metropolitan Life Insurance Company (MetLife) sold 68,816 Exelixis shares in Q1 2022, an estimated $1.26M.
- Metropolitan Life Insurance Company (MetLife) first reported a position in Exelixis in Q2 2013 and held it in 35 quarters.
- Metropolitan Life Insurance Company (MetLife)'s Exelixis position peaked at $3.36M in Q1 2017.
- 364 funds tracked by Wall St. Rank held Exelixis as of Q1 2022.
Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q1 2022, filed 12 May 2022.